|
Harold E. Selick, Ph.D., Chief Executive Officer and George F. Tidmarsh, M.D., Ph.D., President of Threshold Pharmaceuticals [THLD] rings the closing bell. Company Celebrates Initial Public Offering.
|
| |
Harold E. Selick, Ph.D., Chief Executive Officer and George F. Tidmarsh, M.D., Ph.D., President of Threshold Pharmaceuticals [THLD] rings the closing bell.
|
Threshold Pharmaceuticals
Harold E. Selick, Ph.D.,
Chief Executive Officer and
George F. Tidmarsh, M.D., Ph.D.,
President
Rings The NASDAQ Stock Market Closing Bell
Wednesday, February 10, 2005
at NASDAQ's MarketSite
in New York City.
Threshold Pharmaceuticals |
| |
Additional Photographs & Reprint Permissions |
Archived MarketSite Events |
Summary Quote
NASDAQ is proud to welcome Dr. Selick and Dr. Tidmarsh of Threshold Pharmaceuticals [THLD] to the closing bell in celebration of the company's listing on The NASDAQ Stock Market. Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics based on Metabolic Targeting, a powerful scientific approach that offers broad potential to treat most solid tumors and certain other diseases.
About Threshold Pharmaceuticals [THLD]:
Threshold Pharmaceuticals is focused on the discovery, development, and commercialization of small molecule therapeutics based on "Metabolic Targeting". This approach targets abnormal glucose metabolism - a fundamental property of most solid tumors and other diseases. The Company's initial focus is the treatment of cancer and benign prostatic hyperplasia (BPH), a disease characterized by overgrowth of the prostate. Metabolic Targeting provides the opportunity to treat not only rapidly dividing tumor cells, but also the slowly dividing tumor cells that generally evade traditional therapies and ultimately contribute to relapse.
Reprints
|
